Breast Cancer Clinical Trial
— PIKHER2Official title:
A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001
Verified date | March 2017 |
Source | Institut Paoli-Calmettes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is based upon the following points:
1. Resistance to trastuzumab, either primary or secondary, is a clinically relevant issue.
2. PI3K/AKT activation, due to loss of expression/function of PTEN and/or activating
mutations of PIK3CA, is a mechanism of resistance with clinical relevance in breast
cancer. Such activation can be detected by:
- IHC evaluation of PTEN protein expression
- genotyping of PIK3CA exon 9 and 20
- IHC evaluation of phospho-AKT expression
3. BKM120 is an effective PI3K inhibitor. BKM120 and anti-HER2 therapy may have a
synergistic antitumor activity in preclinical model of HER2+ breast cancer.
4. Lapatinib is an effective anti-HER2 therapy in trastuzumab-resistant disease.
5. For the evaluation of novel targeted therapies, selecting a patient population enriched
for activation of the target to be modulated should allow to maximize the differences
in clinical outcome that are expected in the experimental arm, and thus to minimize the
patient number to include.
6. We propose to test in a phase I/II study the combination of lapatinib and BKM120 in
trastuzumab-resistant HER2+ MBC patients, enriched for activation of PI3K/AKT as
detected by loss of expression of PTEN (IHC), and/or mutation of PIK3CA and/or
overexpression of phospho-AKT (IHC). Only for phase II patients, mutational status will
be an inclusion criteria. For phase I patients molecular status will be a retrospective
exploratory analysis.
Status | Suspended |
Enrollment | 106 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Female or male = 18 years 2. WHO performance status = 1 3. Locally advanced, recurrent or metastatic, histologically confirmed HER2 positive (IHC 3+ or FISH positive) breast cancer after failure of trastuzumab treatment. while on trastuzumab or within 4 weeks since the last infusion of trastuzumab for metastatic disease within 12 months of the last infusion for patients who received trastuzumab as adjuvant or neoadjuvant treatment 4. For the phase II part, progression on trastuzumab must have occurred within 16 weeks before entering this trial. 5. should not have received more than 3 lines of anti-HER2 therapy. 6. For the phase II part, activation of PI3K/AKT pathway 7. capable of understanding the protocol and has signed the informed consent 8. laboratory values within normal range 9. Measurable disease 10. Patients may have received treatment for brain metastases, but must be neurologically stable 11. Baseline LVEF>50% (MUGA or ECHO) 12. Affiliation to social security Exclusion Criteria: 1. Previous treatment with lapatinib, neratinib or a PI3K inhibitor 2. untreated brain metastases. 3. acute or chronic liver, renal disease or pancreatitis 4. any peripheral neuropathy = CTCAE grade 2 5. any of the following mood disorders, or meets the cut-off score of = 10 in the PHQ-9 or a cut-off of = 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9) - Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) - = CTCAE grade 3 anxiety 6. diarrhea = CTCAE grade 2 7. active cardiac disease 8. history of cardiac dysfunction 9. poorly controlled diabetes mellitus (HbA1c > 8 %) 10. Other severe and/or uncontrolled concomitant medical conditions 11. Impairment of gastrointestinal function that may significantly alter the absorption of BKM120 12. been treated with any hematopoietic colony-stimulating growth factors = 2 weeks prior to starting study drug. 13. currently receiving treatment with medication with a known risk prolong the QT interval or inducing Torsades de Pointes 14. currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A 15. receiving chronic treatment with steroids or another immunosuppressive agent. 16. have received chemotherapy or targeted anticancer therapy = 4 weeks (6 weeks for nitrosourea, antibodies [other than trastuzumab] or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy 17. have received small molecule therapeutics (excluding monoclonal antibodies) = 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy 18. have received wide field radiotherapy = 4 weeks or limited field radiation for palliation = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 19. have undergone major surgery = 28 days prior to starting study drug or who have not recovered from side effects of such therapy 20. Known diagnosis of HIV infection 21. History of another malignancy within 3 years 22. Patient is unable or unwilling to abide by the study protocol 23. pregnant or breast feeding women |
Country | Name | City | State |
---|---|---|---|
France | Institut Paoli-Calmettes | Marseille |
Lead Sponsor | Collaborator |
---|---|
Institut Paoli-Calmettes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase Ib: maximum-tolerated dose (MTD) | To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily lapatinib to adult patients trastuzumab-resistant HER2+ locally advanced, recurrent and metastatic breast cancer. | Day 28 | |
Primary | Phase II: objective response rate (ORR) | To determine the efficacy of daily BKM120 in combination with daily lapatinib as measured by objective response rate (ORR), defined by complete response (CR) or partial response (PR) of target and non target lesions according to RECIST V1.1., in patients with activation of PI3K/AKT pathway detected according to one at least of the following criteria, measured on primary or metastatic tissue: PTEN negative by IHC and/or somatic mutations (exons 9 and 20) of PIK3CA and/or Overexpression of phospho-AKT by IHC. | until progression assessed up to 1 year | |
Secondary | safety | Number of patients with adverse events (according to CTCAE V4) | until progression or end of treatment assessed up to 1 year | |
Secondary | clinical benefit (CB) | - To evaluate clinical benefit (CB defined as complete response (CR) + partial response (PR) + Stable disease (SD) > 6 months) | until progression assessed up to 1 year | |
Secondary | progression-free survival (PFS) | - To assess progression-free survival (PFS) | until progression assessed up to 1 year | |
Secondary | pharmacokinetics | - To determine pharmacokinetics profile (CMax, AUC) of oral BKM120 in combination with orally lapatinib and to monitor exposure to lapatinib | D1, D8, D15, D22, D28 post dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |